FKBP

FKBPs are a family of cytosolic immunophilins that catalyze cis-trans isomerization of proline residues (peptidyl-prolyl isomerase/rotamase activity), assisting in protein folding. Their major clinical relevance lies in drug-receptor interactions: Tacrolimus (FK506) binds FKBP12, and this tacrolimus-FKBP12 complex inhibits calcineurin, a calcium/calmodulin-dependent phosphatase. Calcineurin normally dephosphorylates NFAT (nuclear factor of activated T cells), allowing it to translocate to the nucleus and promote IL-2 gene transcription. By inhibiting calcineurin, the tacrolimus-FKBP12 complex blocks IL-2 transcription, suppressing T-cell activation and proliferation—similar in mechanism to cyclosporine, which instead binds cyclophilin. Sirolimus (rapamycin) also binds FKBP12, but this complex inhibits mTOR (mechanistic target of rapamycin) rather than calcineurin, blocking the response to IL-2 and preventing progression from G1 to S phase in T-cells, thus inhibiting T-cell proliferation without affecting IL-2 production. Clinically, tacrolimus and sirolimus (both FKBP12-binding drugs) are used as immunosuppressants in solid organ transplantation to prevent graft rejection. Key adverse effects of tacrolimus include nephrotoxicity, neurotoxicity, hyperglycemia/diabetes, and hypertension, while sirolimus is associated with myelosuppression, hyperlipidemia, and impaired wound healing (notably not nephrotoxic). Understanding FKBP is essential for grasping the distinct mechanisms of calcineurin inhibitors versus mTOR inhibitors, which are frequently tested concepts on USMLE exams regarding immunosuppressive pharmacology.